Novo Holdings
VC Fund
Hellerup, Denmark
Novo Holdings is a holding and investment firm that manages the assets of the Novo Nordisk Foundation. It is a life science investor with a diverse portfolio that includes equities, bonds, real estate, infrastructure, and private investments.
- Total investments:
- 410
- Last investment:
- Lead investor:
- 40%
- Fund size:
- $165M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Novo Holdings invests in
Stages Novo Holdings invests in
Countries Novo Holdings invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 17 contacts → | |||
Round size
- Series A
- $9.5M–$133M
- Series B
- $15M–$135M
- Series C
- $30M–$118M
Investment Focus
Industry
- Biotechnology 168 (41%)
- Health Care 125 (30%)
- Medical 75 (18%)
- Pharmaceutical 64 (16%)
- Therapeutics 62 (15%)
Stage
- Series A 93 (23%)
- Series B 71 (17%)
- Series C 51 (12%)
- Venture - Series Unknown 33 (8%)
- Seed 18 (4%)
Country
- United States 121 (30%)
- Denmark 38 (9%)
- United Kingdom 23 (6%)
- Switzerland 11 (3%)
- Sweden 7 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Emmanuelle Coutanceau
Partner Novo Seeds
|
Partner Novo Seeds | Total investments: 10 | Find email | |
Steve Collins
National Account Executive
|
National Account Executive | Total investments: 1 | Find email | |
Thomas Dyrberg
Partner
|
Partner | Total investments: 17 | Find email | |
Thomas Grotkjær
Investor & Principal
|
Investor & Principal | Total investments: 12 | Find email | |
Abhijeet Lele
Senior Partner and Head of US Principal Investments
|
Senior Partner and Head of US Principal Investments | Total investments: 6 | Find email | |
| See all 17 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics against challenging disease targets. | $310M / Series C / Oct 15, 2026 | ||
| AnaCardio is a clinical stage biopharmaceutical company developing novel drugs to treat heart failure. | $70.8M / Series B / Sep 30, 2026 | ||
| Breye Therapeutics, a Danish-based biopharmaceutical firm in the clinical stages, is working to provide cutting-edge oral treatments for the management of retinal vascular diseases. | $76.7M / Series A / Sep 29, 2026 | ||
| ForYou Medical develops and manufactures Advanced wound care dressings, hemostats, and biodegradable materials. Foryou is committed to offering comprehensive care to customers and patients. | Private Equity / Sep 10, 2026 | ||
CaMaRa
|
CaMaRa is a biotechnology company developing new medicines for cardiometabolic conditions, including obesity, diabetes and kidney disease. | Seed / Sep 09, 2026 | |
| Expedition Therapeutics operates as an unincorporated association. | $115M / Series B / Aug 05, 2026 | ||
| Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars. The formulation creates a recombinant hepatocyte growth factor which accelerates the healing process, providing healthcare providers noninvasive therapeutic treatment. | $118M / Series B / Jul 28, 2026 | ||
| Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout. | $130M / Series B / Jul 22, 2026 | ||
| The Protein Brewery is a high-tech company that specializes in developing and making animal-free- based protein in a sustainable way. It's a spin-out from BioscienZ and is commercializing innovative protein production using fermentation. It was founded by Wim de Laat in 2019 and is based in Breda, Noord-Brabant, The Netherlands. | $20.5M / Series B / Jun 29, 2026 | ||
| HSTpathways will raise the level of excellence for providing Information Technology and IT Services to Outpatient Healthcare Providers. In every industry, a clear market leader emerges and delivers exceptional value and service to their customers. HSTpathways demonstrates its leadership with superior solutions for both the enterprise multi-facilitycustomer as well as the freestanding surgical centers. Together, with customers as partners, HSTpathways will continually improve upon its Information Technology to reflect best practices. HSTpathways will become an important Strategic Business Asset and indispensable to senior and executive management.HSTpathways' leadership, management, and staff will tirelessly pursue quality improvement processes. They continuously strive to develop reliable software and provide excellent customer service in a way that is consistent, repeatable, and cost effective for their customers. They are committed to listening to their customers and to understanding how the industry is evolving. They will incorporate these new requirements and changes as part of regular and prompt software updates. As a customer, you will experience this commitment by their actions, their products, and by the attitudes of everyone at HSTpathways. | Private Equity / Jun 05, 2026 | ||
| See all 410 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Novo Holdings invest in?
Novo Holdings invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 410 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Novo Holdings invest in?
Novo Holdings typically joins rounds of $9.5M–$133M at Series A, $15M–$135M at Series B and $30M–$118M at Series C. These are whole funding-round sizes, not Novo Holdings's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Novo Holdings took part in.
How do I contact Novo Holdings?
Public channels for Novo Holdings include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Novo Holdings?
The team at Novo Holdings includes Emmanuelle Coutanceau (Partner Novo Seeds), Steve Collins (National Account Executive) and Thomas Dyrberg (Partner), among 17 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
